Therapeutic potential of Erythropoietin for IBD

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591980
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Nara Medical University
• Principal Investigator: NAKAMURA Shinji 奈良県立医科大学, 医学部, 助教 (30423924)
• Co-Investigator(Kenkyū-buntansha): SHO Masayuki 奈良県立医科大学, 消化器・総合外科, 准教授 (50364063) ; KOYAMA Fumikazu 奈良県立医科大学, 中央内視鏡・超音波部, 准教授 (40316063) ; UEDA Takeshi 奈良県立医科大学, 消化器・総合外科, 医員 (40526810) ; NISHIGORI Naoto 奈良県立医科大学, 消化器・総合外科, 医員 (70570977) ; INOUE Takashi 奈良県立医科大学, 消化器・総合外科, 医員 (60623478) ; NAKAMOTO Takayuki 奈良県立医科大学, 消化器・総合外科, 医員 (70646091) ; FUJII Hisao 奈良県立医科大学, 中央内視鏡・超音波部, 教授 (40156823) ; NAKAJIMA Yoshiyuki 奈良県立医科大学, 消化器・総合外科, 教授 (00142381)
• Research Collaborator: YOSHIKAWA Syusaku ; INATSUGI Naoki
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: エリスロポエチン / IBD / 腸管 / 組織再生

Outline of Final Research Achievements

The aim of this study was to investigate the therapeutic potential of erythropoietin (EPO) for the treatment of IBD. Mice treated with rhEPO significantly survived compared with control mice induced by 5-day DSS. Histological analysis confirmed that EPO treatment reduced the colonic inflammation. EPO treatment significantly downregulated the local expressions. In a 4-day DSS-induced colitis model, rhEPO significantly improved the recovery of body weight loss compared to controls. PCNA expression was significantly upregulated in the colon tissue from mice treated with rhEPO. In addition, rhEPO increased the growth of cultured human colon epithelial cells in a dose-dependent manner. Furthermore, EPO-receptor expression was confirmed in human IBD colon tissues. Conclusion. Three major functions of EPO, hematopoiesis, anti-inflammation and regeneration, may produce significant effects on intestinal inflammation, therefore suggesting that EPO might be useful for IBD.

Free Research Field

大腸肛門病学